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the prevalence and distribution of COPD world‑
wide has become available. However, most data 
have been derived from expert opinions, and they 
differ significantly in terms of the population, 
especially regarding age, concomitant diseases, 
race, as well as diagnostic criteria of COPD.3 This 
INTRODUCTION The prevalence of chronic ob‑
structive pulmonary disease (COPD) is estimated 
at 7.6%, regardless of diagnostic criteria.1 COPD 
is projected to rank fifth worldwide in terms of 
disease burden and third regarding the mor‑
tality rate.2 An increasing body of evidence on 
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ABSTRACT
INTRODUCTION The incidence of chronic obstructive pulmonary disease (COPD) in patients treated with 
percutaneous coronary intervention (PCI) is underestimated, and the effect of COPD on atherosclerosis 
and the outcomes of PCI is not fully understood.
OBJECTIVES The aim of this study was to assess the impact of COPD on periprocedural outcomes of 
PCI, as well as its relationship with clinical presentation and the type of coronary artery lesions.
PATIENTS AND METHODS Data were prospectively collected using a national electronic registry of 
PCI procedures performed in Poland between January 2015 and December 2016. Out of the 221 187 
PCIs, 5594 patients had been diagnosed with COPD before the intervention.
RESULTS Patients with COPD were older than those without COPD (mean [SD] age, 70.3 [9.9] years vs 
67 [10.8] years; P <0.001) and more often were males (72.3% vs 67.8%; P <0.001). Non–ST ‑segment 
elevation myocardial infarction (NSTEMI) was a more common clinical presentation of coronary artery 
disease (CAD) in the COPD group, while ST ‑segment elevation myocardial infarction (STEMI) occurred 
more frequently in the non ‑COPD group. Multivessel disease (MVD) with or without left main coronary 
artery (LMCA) involvement and separate LMCA was diagnosed more often in the COPD group. At baseline, 
the culprit lesion was more often restenosis and in ‑stent thrombosis in the COPD group, whereas de ‑novo 
lesion—in the non ‑COPD group. The rates of periprocedural mortality and myocardial infarction did not 
differ between the groups with and without COPD (0.13% vs 0.12%, P = 0.88 and 0.53% vs 0.45%, P = 
0.39, respectively). COPD was found to be an independent predictor of restenosis assessed before PCI 
in patients with a history of PCI (P = 0.006).
CONCLUSIONS Patients with COPD diagnosed before PCI are at an increased risk of MVD with or without 
LMCA involvement and NSTEMI. Restenosis and in ‑stent thrombosis occur more often in patients with 
COPD before PCI.
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Statistical analysis All continuous variables were 
evaluated using the Kolmogorov–Smirnov test 
to confirm normal distribution. Continuous vari‑
ables were presented as mean (SD) and median 
(interquartile range). Categorical variables were 
presented as numeric values and per centages. 
Continuous variables were compared with the t 
test and the Mann–Whitney test, whereas cat‑
egorical variables—with the χ2 test. Univariate 
and multivariable analyses were performed to 
identify predictors of restenosis, in ‑stent throm‑
bosis, and multivessel disease (MVD) with or 
without the left main coronary artery (LMCA) 
involvement and separate LMCA disease in all 
patient groups. Additionally, we analyzed pre‑
dictors of restenosis and in ‑stent thrombosis in 
the subgroup of patients with COPD and a histo‑
ry of PCI. The following variables were analyzed: 
age, sex, diabetes, previous stroke, MI, PCI, cor‑
onary artery bypass grafting (CABG), smoking 
status, psoriasis, kidney disease, COPD, vascular 
access, fractional flow reserve, intravascular ul‑
trasound, optical coherence tomography, throm‑
bectomy, rotablation, pharmacological treatment, 
TIMI flow, contrast and radiation dose, peripro‑
cedural complications, clinical presentation of 
CAD, and the type of coronary artery lesions in‑
cluding distribution, bifurcations, and chronic 
total occlusions (CTOs). We assessed the same 
factors for the analysis of the PCI subgroups.
RESULTS Characteristics of patients with and with-
out chronic obstructive pulmonary disease We an‑
alyzed 221 187 PCIs performed in Poland be‑
tween January 1, 2015, and December 31, 2016. 
Among all patients who underwent PCI, there 
were 5594 patients (2.5%) with COPD. The high‑
est incidence of COPD was reported in patients 
aged between 70 and 80 years (3.4%) and 80 and 
90 years (3.3%) (FIGURE 1A). Moreover, the high‑
est incidence was observed  in patients with 
non–ST ‑segment elevation MI (NSTEMI) pre‑
sentation of CAD (3.36%), as compared with 
other clinical presentations (FIGURE 1B). Finally, 
the highest incidence was noted for patients with 
separate LMCA involvement (4.06%) and MVD 
with LMCA involvement (3.55%), as compared 
with those with single ‑vessel disease (SVD) and 
MVD without LMCA involvement (FIGURE 1C). De‑
mographic characteristics, concomitant diseas‑
es, and clinical presentation of patients with and 
without COPD are presented in TABLE 1.
Periprocedural variables Periprocedural data, in‑
cluding vascular access, pharmacological thera‑
py, and angiographic results, are presented in 
TABLES 1 and 2. In the COPD group, radial access 
was more often used in patients with stable an‑
gina (SA) (P = 0.02), while it was used less fre‑
quently in those with ST ‑segment elevation MI 
(STEMI) (P = 0.03). Pharmacological treatment 
before hospitalization and during PCI is pre‑
sented in TABLE 2.
hampers a conclusive comparison of the prev‑
alence of COPD between different countries. 
The Global Initiative for Chronic Obstructive 
Lung Disease has established a definition of 
COPD for epidemiological purposes.2 Early di‑
agnosis is crucial to encourage smoking cessa‑
tion, appropriate pharmacotherapy, and phys‑
ical exercise.4,5 The diagnosis of COPD increas‑
es the risk of and mortality from cardiovascular 
diseases by an odds ratio of 2.7 and 1.68, respec‑
tively.6 The prevalence of coronary artery disease 
(CAD) among patients with COPD is estimat‑
ed at 10% to 23%,7 while its incidence among 
patients undergoing PCI—at 2.4% to 10%.8-11 
A study on a group of 119 patients demonstrated 
that the real prevalence of COPD confirmed by 
spirometry in hospitalized patients with CAD is 
34%, of which 87% had not been not previous‑
ly diagnosed with COPD.12 Therefore, the aim 
of the current study was to assess the impact 
of COPD on periprocedural outcomes of percu‑
taneous coronary interventions (PCIs) and its 
relationship with clinical presentation and the 
type of coronary artery lesions in a large group 
of patients.
PATIENTS AND METHODS Study population, de-
sign, and definitions We collected and prospec‑
tively analyzed national data on all patients who 
underwent PCI in Poland between January 2015 
and December 2016. Data on PCI procedures were 
obtained from the Polish registry ORPKI (in Pol‑
ish, Ogólnopolski Rejestr Procedur Kardiologii 
Inwazyjnej), which is coordinated nationwide by 
Jagiellonian University Medical College (Kraków, 
Poland) in cooperation with the Association of 
Cardiovascular Interventions of the Polish Car‑
diac Society.13,14 Although the ORPKI database 
is voluntary, the majority of all catheterization 
laboratories in Poland (98%) record their data in 
the registry. The Polish database has been con‑
tinuously upgraded over consecutive years, and 
in 2016, it reached more than 250 clinical, pro‑
cedural, and outcome variables, with more than 
110 000 new PCI records added each year. 
COPD was defined on the basis of a previous‑
ly established diagnosis.2 All indices recorded in 
the ORPKI database are derived from the peri‑
procedural data provided by the operator after 
each procedure. Furthermore, we did not collect 
follow ‑up data after discharge. Periprocedur‑
al major adverse cardiac events (MACEs) were 
defined as the combination of all ‑cause death, 
myocardial infarction (MI), and cerebral stroke. 
The definition of MI was in line with the third 
universal definition of MI and remained at the 
descretion of the operator.15 The Thrombolysis 
in Myocardial Infarction (TIMI) grade flow was 
used to estimate procedural TIMI effectiveness, 
and the treatment was considered effective when 
the TIMI flow grade 3 was obtained after the pro‑
cedure. The study protocol was approved by an in‑
stitutional review board.
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FIGURE 1  
A – incidence of chronic 
obstructive pulmonary 
disease (COPD) 
according to age;  
B – incidence of COPD 
according to clinical 
presentation of coronary 
artery disease before 
percutaneous coronary 
intervention;  
C – incidence of COPD 
according to localization 
of atherosclerotic lesions 
in coronary arteries 
Abbreviations: LMCA, 
left main coronary artery; 
MVD, multivessel 
disease; NSTEMI, 
non–ST‑segment 
elevation myocardial 
infarction; SA, stable 
angina; STEMI, ST‑
‑segment elevation 
myocardial infarction; 
SVD, single ‑vessel 
disease; UA, unstable 
angina 
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with the SA subgroup both in the COPD (P = 0.001) 
and non ‑COPD groups (P <0.001). The rate of de‑
‑novo lesions was higher in patients with SA com‑
pared with those with ACS only in the non ‑COPD 
group (P <0.001). The subgroups of patients with 
SA showed no significant differences in the rates 
of lesion type at baseline between the COPD and 
non ‑COPD groups. However, when comparing 
the ACS subgroups, the non‑COPD group showed 
a higher rate of de ‑novo lesions (P = 0.03) and 
a lower rate of in ‑stent thrombosis (P = 0.008).
We did not find significant differences in 
the rates of restenosis depending on the type of 
procedure (drug ‑eluting stenting, bare metal stent‑
ing, bioresorbable scaffold implantation, plain old 
balloon angioplasty, and drug ‑eluting balloon im‑
plantation) between the SA and ACS subgroups in 
the COPD group on admission. In the non ‑COPD 
group at baseline, restenosis after drug ‑eluting 
stent implantation was reported more frequently 
in patients with ACS (P = 0.06), while restenosis 
after bare metal stent implantation—in patients 
with SA (P = 0.01). There were also no significant 
differences in the frequency of a particular type 
of restenosis in the SA and ACS subgroups of pa‑
tients between the COPD and non ‑COPD groups 
at baseline. Patients with SA underwent more CTO 
Specification of the culprit lesion The location of 
coronary atherosclerosis on angiography is pre‑
sented in TABLE 3. There were 1549 patients with SA 
diagnosed before PCI in the COPD group (27.7%) 
and 59 503 patients with SA in the non ‑COPD 
group (27.6%). Patients with acute coronary syn‑
drome (ACS) at baseline constituted 71.1% (n = 
3980) of the COPD group and 71.3% (n = 153 967) 
of the non ‑COPD group. 
At baseline, we recorded 1703 de ‑novo lesions 
(94.3%), 101 cases of restenosis (5.6%), and 1 case 
of in ‑stent thrombosis (0.05%) of the overall 1805 
treated lesions among patients with SA presenta‑
tion of CAD in the COPD group. In the non ‑COPD 
group of patients with SA diagnosed before PCI, 
there were 62 618 de ‑novo lesions (95.1%), 3192 
cases of restenosis (4.8%), and 45 cases of in ‑stent 
thrombosis (0.06%). At baseline, the ACS sub‑
group of patients included 4411 patients with de‑
‑novo lesions (94%), 235 patients with resteno‑
sis (5%), and 45 patients with in ‑stent thrombo‑
sis (0.9%) in the COPD group, and 160 674 pa‑
tients with de ‑novo lesions (94.7%), 7854 pa‑
tients with restenosis (4.6%), and 1092 patients 
with in ‑stent thrombosis (0.6%) in the non ‑COPD 
group. The rate of in ‑stent thrombosis was high‑
er at baseline in the ACS subgroup in comparison 
TABLE 1 Baseline demographic and clinical characteristics of the study groups
Parameter COPD (+)
(n = 5594)
COPD (–)
(n = 215 593)
P value
Age, y Mean (SD) 70.3 (9.3) 67.0 (10.8) <0.0001
Median (IQR) 70 (64–77) 67 (60–75)
Sex, males 4045/5592 (72.3) 146 095/215 539 (67.8) <0.0001
Diabetes, n (%) 2041/5594 (36.5) 50 636/215 593 (23.5) <0.0001
Hypertension 4598/5594 (82.2) 152 810/215 593 (70.9) <0.0001
Previous cerebral stroke 414/5594 (7.4) 6876/215 593 (3.2) <0.0001
Previous MI 2103/5594 (37.6) 66 852/215 593 (31.0) <0.0001
Previous PCI 2126/5594 (38.0) 80 318/215 593 (37.2) 0.25
Previous CABG 405/5594 (7.2) 13 687/215 593 (6.3) 0.007
Smoking status 1888/5594 (33.7) 40 686/215 593 (18.9) <0.0001
Psoriasis 48/5594 (0.8) 821/215 593 (3.8) <0.0001
Kidney disease 918/5594 (16.4) 11 209/215 593 (5.2) <0.0001
Indication for PCIa
Stable angina 1549/5587 (27.7) 59 503/215 269 (27.6) 0.88
Unstable angina 1602/5587 (28.7) 64 115/215 269 (29.8) 0.07
NSTEMI 1384/5587 (24.8) 39 732/215 269 (18.4) <0.0001
STEMI 994/5587 (17.8) 50 120/215 269 (23.3) <0.0001
Others 58/5587 (1.0) 1799/215 269 (0.8) 0.1
Vascular access
Femoral artery 1344/5594 (24.0) 55 292/215 593 (25.6) 0.006
Left radial artery 869/5594 (15.5) 35 910/215 593 (16.6) 0.02
Right radial artery 3323/5594 (59.4) 122 806/215 593 (56.9) <0.001
Other 58/5594 (1.0) 1585/215 593 (0.7) 0.009
Data are presented as number (percentage) of patients unless otherwise indicated.
Abbreviations: CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; IQR, interquartile 
range; MI, myocardial infarction; PCI, percutaneous coronary intervention; others, see FIGURE 1
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and Cx were performed more often in the MVD 
group, whereas PCI of the right coronary artery was 
more frequent in the SVD group (P <0.001). Peri‑
procedural indices, including the type of the cul‑
prit lesion, PCI procedure, and stent according to 
the location, are presented in TABLE 3. 
After adjustment for the type of an implant‑
ed stent, there were no significant differences in 
the restenosis rate assessed before stent implan‑
tation between the COPD and non ‑COPD groups 
in the subgroups undergoing drug ‑eluting stent, 
bare metal stent, or bioresorbable scaffold implan‑
tation. However, we observed higher restenosis 
rates assessed before PCI in patients undergoing 
plain balloon angioplasty or drug ‑eluting balloon 
angioplasty when performed on the Cx (60% vs 
28.5%, P = 0.03).
procedures (5.9% vs 4.3%, P = 0.01), bifurcations 
(7.9% vs 6.1%, P = 0.01), and rotablations (1.2% vs 
0.3%, P <0.001) compared with those with ACS. 
At baseline, patients with ACS underwent PCI of 
the LMCA more often (5.2% vs 3.5%, P = 0.007) 
than those with SA. PCIs of CTO and bifurcated 
lesions was performed more often in men than in 
women (5.3% vs 3.4%, P = 0.002 and 7.2% vs 5.0%, 
P = 0.002, respectively), while thrombectomy oc‑
curred more often in women than in men (2.2% vs 
3.4%, P = 0.01). PCIs of the LMCA and circumflex 
artery (Cx) were performed more often in patients 
with NSTEMI, while of the right coronary artery—
in patients with STEMI (P <0.001). Bifurcations 
were treated with PCI more frequently in the MVD 
group compared with the SVD group (P <0.001). 
PCI of the LMCA, left anterior descending artery, 
TABLE 2 Baseline characteristics of the study groups
Parameter COPD (+)
(n = 5594)
COPD (–)
(n = 215 593)
P value
CTO 267/5594 (4.8) 9053/215 593 (4.2) 0.03
Bifurcation 369/5594 (6.6) 11 525/215 593 (5.3) <0.0001
FFR 78/5594 (1.4) 3180/215 593 (1.5) 0.62
IVUS 40/5594 (0.7) 1842/215 593 (0.8) 0.26
OCT 7/5594 (0.1) 393/215 593 (0.18) 0.32
Rotablation 29/5594 (0.5) 946/215 593 (0.44) 0.37
Coronary angiography
SVD 3381/5152 (65.6) 135 320/195 724 (69.1) <0.0001
MVD, LMCA (–) 1409/5152 (27.3) 50 847/195 724 (26.0) 0.02
MVD, LMCA (+) 288/5,152 (5.6) 7812/195 724 (4.0) <0.0001
Separate LMCA disease 74/5152 (1.4) 1745/195 724 (0.9) <0.0001
Pharmacological treatment before hospitalization
ASA 3255/5594 (58.2) 105 118/215 593(48.7) <0.0001
UFH 860/5594 (15.4) 31 912/215 593 (14.8) 0.23
LMWH 95/5594 (1.7) 1966/215 593 (0.9) <0.0001
P2Y12 inhibitors Clopidogrel 3593/5594 (64.2) 118 212/215 593 (54.8) <0.0001
Ticagrelor 227/5594 (4.0) 10 907/215 593 (5.0) <0.001
Prasugrel 22/5594 (0.4) 1143/215 593 (0.5) 0.23
GP IIb/IIIa inhibitor 455/4672 (9.7) 21 047/176 775 (11.9) <0.0001
Bivalirudin 0/5594 (0) 17/215 593 (0.003) 0.48
Thrombolysis 1/4677 (0.02) 43/177 114 (0.02) 0.9
Pharmacological treatment during PCI
ASA 1043/5594 (18.6) 36 511/215 593 (16.9) <0.001
UFH 5070/5594 (90.6) 181 503/215 593 (84.2) <0.0001
LMWH 135/5594 (2.4) 8371/215 593 (3.9) <0.0001
P2Y12 inhibitors Clopidogrel 2426/5434 (44.6) 90 659/215 593 (42.0) <0.0001
Ticagrelor 132/5434 (2.4) 10 227/215 593 (4.7) <0.0001
Prasugrel 28/5434 (0.5) 973/215 593 (0.4) 0.48
GP IIb/IIIa inhibitors 13/5594 (0.2) 836/215 593 (0.4) 0.06
Bivalirudin 14/5594 (0.2) 556/215 593 (0.2) 0.91
Thrombolysis 8/5594 (0.1) 341/215 593 (0.1) 0.77
Data are presented as number (percentage) of patients.
Abbreviations: ASA, acetylsalicylic acid; CTO, chronic total occlusion; FFR, fractional ‑flow reserve; GP, glycoprotein; 
IVUS, intravascular ultrasound; LMWH, low ‑molecular ‑weight heparin; OCT, optical coherence tomography; UFH, 
unfractionated heparin; others, see FIGURE 1 and TABLE 1
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Clinical presentation of coronary artery disease be-
fore percutaneous coronary intervention Consider‑
ing the clinical presentation of CAD before PCI, 
the number of patients with NSTEMI was high‑
er than that of patients with STEMI in the COPD 
group. There were no significant differences in 
the frequency of SA and unstable angina between 
the COPD and non ‑COPD groups (TABLE 1).
Predictors of restenosis and in -stent thrombo-
sis The results of the multivariable analysis of 
predictors of restenosis and in ‑stent thrombo‑
sis performed for the whole study group are pre‑
sented in FIGURES 2 and 3. The results of the multi‑
variate analysis for the subgroup of patients with 
a history of PCI are presented in FIGURE 4A and 4B.
Predictors of multivessel disease To analyze 
the risk factors for the distribution of athero‑
sclerotic lesions in the coronary arteries, we di‑
vided all patients into the groups of patients with 
SVD and those with MVD with or without LMCA 
involvement and separate LMCA involvement. 
The multivariable analysis of the predictors of 
atherosclerotic lesion distribution in the coro‑
nary arteries is presented in FIGURE 5.
DISCUSSION The main finding of our study is 
that the incidence of COPD in patients undergo‑
ing PCI in Poland is 2.5% ; however, this result is 
likely to be underestimated. We also confirmed 
that patients with COPD have an increased inci‑
dence of proatherosclerotic risk factors. The third 
finding is that patients with COPD were character‑
ized by an increased level of restenosis, in ‑stent 
thrombosis, and NSTEMI as a clinical presenta‑
tion of CAD at baseline. The multivariable anal‑
ysis confirmed that COPD was an independent 
Periprocedural outcomes At  baseline, there 
were more patients with TIMI flow grade 0 
(18% vs 21%, P <0.001) and 1 (12.3% vs 13.5%, 
P = 0.007) in the non ‑COPD group compared 
with the COPD group, while the number of pa‑
tients with TIMI flow grade 3 was lower (51.0% 
vs 46.5%; P  <0.001). The  percentage of pa‑
tients with an occluded coronary artery at base‑
line (TIMI flow grades 0 and 1) was higher in 
the non ‑COPD group compared with the COPD 
group (34.5% vs 30.1%, P <0.001). 
Although the proportion of patients with 
TIMI flow grade 3 before PCI was higher in 
the COPD group (51% vs 46.5%, P <0.001), 
the frequency of postprocedural TIMI flow grade 
3 was higher in the non ‑COPD group (92.6% vs 
94%; P <0.001), indicating a greater effectiveness 
of PCI (Δ = 47.5% in the non ‑COPD group and 
Δ = 41.6% in the COPD group). We also demon‑
strated that blood flow restoration assessed as 
TIMI flow grade 3 after the procedure was more 
common in patients with PCI of the left anterior 
descending artery (P = 0.001), mainly the proxi‑
mal segment (P = 0.007) and Cx (P = 0.01), com‑
pared with the other arteries. Additionally, PCI 
effectiveness, expressed as the achievement of 
TIMI flow grade 3 after the procedure, was high‑
er in patients with SA at baseline compared with 
those with ACS (97.8% vs 91.8%, P  <0.001). It 
was also better in the NSTEMI group as com‑
pared with the STEMI group (88.1% vs 92.2%, 
P = 0.001). 
The periprocedural mortality rate was similar 
between the COPD and non ‑COPD groups (0.53% 
vs 0.45%, P = 0.39). Also, the rate of periproce‑
dural MI did not differ between the COPD and 
non ‑COPD groups (0.13% vs 0.12%, P = 0.88).
TABLE 3 Culprit lesion type according to localization in patients with and without chronic obstructive pulmonary disease
Location Total number of lesions De novo Restenosis In ‑stent thrombosis
COPD 
(+)
COPD 
(–)
P value COPD 
(+)
COPD  
(–)
P value COPD 
(+)
COPD 
(–)
P 
value
COPD 
(+)
COPD 
(–)
P value
Overall 6542 
(100)
237 956 
(100)
_ 6153 
(94.0)
225 647 
(94.8)
0.005 341 
(5.2)
11 137 
(4.7)
0.04 48 (0.7) 1172 
(0.5)
0.006
RCA 2164 
(33.1)
77 854 
(32.7)
0.53 2005 
(32.6)
73 392 
(32.5)
0.91 133 (39) 4086 
(36.7)
0.38 26 (54.2) 376 
(32.1)
0.001
LMCA 268 
(4.1)
6429 
(2.7)
<0.0001 256 
(4.2)
6132 
(2.7)
<0.0001 11 (3.2) 271 (2.4) 0.35 1 (2.0) 26 (2.2) 0.95
LAD 2268 
(34.7)
89 140 
(37.5)
<0.0001 2150 
(34.9)
84 613 
(37.5)
<0.0001 108 
(31.7)
4005 
(36.0)
0.1 10 (20.8) 322 
(27.5)
0.31
Cx 1676 
(25.6)
58 190 
(24.4)
0.03 1592 
(25.9)
52 876 
(23.4)
<0.0001 75 
(22.0)
2253 
(20.2)
0.42 9 (18.7) 209 
(17.8)
0.87
IM 81 (1.2) 3367 
(1.4)
0.22 81 (1.3) 3209 
(1.4)
0.48 3 (0.9) 139 (1.2) 0.54 0 (0) 19 (1.6) 0.37
SvG 71 (1.1) 2545 
(1.0)
0.9 60 (1.0) 2171 
(1.0)
0.91 10 (2.9) 354 (3.2) 0.79 1 (2.0) 20 (1.7) 0.83
LIMA/
RIMA
11 (0.2) 431 
(0.2)
0.8 9 (0.1) 402 (0.2) 0.55 1 (0.3) 29 (0.3) 0.9 1 (2.0) 0 (0) <0.0001
Data are presented as number (percentage) of patients.
Abbreviations: Cx, circumflex artery; IM, intermediate artery; LAD, left anterior descending artery; LIMA, left internal mammalian artery; RCA, right 
coronary artery; RIMA, right internal mammalian artery; SvG, saphenous vein graft; others, see FIGURE 1, TABLE 1, and TABLE 2
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TIMI flow grade 3 after the procedure, was signif‑
icantly higher in the non ‑COPD group compared 
with the COPD group.
Incidence of chronic obstructive pulmonary disease and 
general characteristics of these patients A meta‑
‑analysis of studies on the general population, 
published between 1990 and 2004 and regard‑
ing the prevalence of COPD, revealed geograph‑
ical disparities and differing methodologies.16 
The prevalence of COPD was estimated at 7.6%, 
independently of the defined diagnostic criteria. 
predictor of an increased risk of restenosis in pa‑
tients who had undergone PCI in the past or are 
currently referred for PCI, irrespective of the clini‑
cal presentation. Despite this, patients with COPD 
were initially more likely to be treated with aspi‑
rin, clopidogrel, and low ‑molecular ‑weight hepa‑
rin. Additionally, MVD with or without LMCA in‑
volvement and separate LMCA involvement was 
diagnosed in patients with COPD more often com‑
pared with those without COPD. The effectiveness 
of PCI procedures in the overall group of patients 
undergoing PCI, assessed as the achievement of 
FIGURE 2 Predictors of in ‑stent thrombosis in patients referred for percutaneous coronary intervention on admission  
Abbreviations: ACS, acute coronary syndrome; CI, confidence interval; OR, odds ratio; others, see TABLE 1
FIGURE 3 Predictors of restenosis in patients referred for percutaneous coronary intervention on admission  
Abbreviations: PCI, percutaneous coronary intervention; others, see TABLE 1 and FIGURE 2 
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<0.0001
<0.0001
<0.0001
0.006
0.003
<0.0001
0.854
1.842
11.436
1.433 1.235–1.663
1.403
0.824
1.121–1.757
0.718–0.946
14.981 11.107–20.207
OR 95% CI P value
15 20-10 -5 5 10
ORIGINAL ARTICLE Impact of COPD on patients undergoing PCI 31
mortality rates, higher rehospitalization rates, and 
poorer health status 1 year after MI.11,25 These out‑
comes were attributed to the lower rates of guide‑
line therapies prescribed at discharge.25 The cur‑
rent results may be connected with a poorer aware‑
ness of smokers about the causes of their short‑
ness of breath and therapeutic possibilities. More‑
over, patients referred for PCI on admission often 
try to consciously conceal the signs of pulmo‑
nary diseases or diseases connected with smok‑
ing, such as COPD, as they fear the disapproval 
The prevalence of COPD increases with age.17 In 
a retrospective study, in which COPD was iden‑
tified by the International Classification of Dis‑
eases codes, the rate of COPD was 7.17% among 
patients undergoing PCIs.18 It was demonstrat‑
ed that the incidence of COPD varied between 
2.4% and 10% in patients with SA, and between 
5.3% and 15.6% in patients with ACS.9,11,18-24 Pa‑
tients with COPD treated with PCI showed a high‑
er number of comorbidities and more often suffer 
from CAD.25 They were also found to have higher 
FIGURE 4 Multivariable analysis of restenosis and in ‑stent thrombosis predictors in patients with a history of percutaneous coronary intervention 
(PCI) who were referred for PCI on admission; A – predictors of in ‑stent thrombosis; B – predictors of restenosis 
Abbreviations: see TABLE 1 and FIGURE 2
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conflicting results.29-32 Similar results were de‑
scribed in patients with restenosis after carot‑
id artery stenting.33 One of the possible expla‑
nations is that smokers have a reduced sensitiv‑
ity to restenosis, and the second is that smokers 
are more reluctant to seek medical attention de‑
spite recurrent angina.34 The effect of smoking on 
MACEs is also controversial. Some investigators 
found that smoking increases the risk of MACEs, 
while others did not.35-38 
Another explanation of the increased rate of 
restenosis and in ‑stent thrombosis could be in‑
adequate cardiac therapy due to poor compli‑
ance, as well as pulmonary therapy due to under‑
diagnosis resulting in hypoxia and further conse‑
quences leading to progression of atherosclero‑
sis. Enriquez et al25 demonstrated that patients 
with COPD were significantly less likely to receive 
β ‑blockers, aspirin, and statins at discharge after 
PCI. Since our registry does not include such data, 
we were unable to conduct this analysis. It was 
also reported that patients with COPD and ACS 
frequently show atypical presentation (mainly 
dyspnea) that could be misinterpreted as COPD 
exacerbations.24 In addition, although COPD was 
associated with an older age and a worse cardio‑
vascular risk profile, it was not independently 
associated with increased in ‑hospital mortali‑
ty rates. However, it was linked to a higher inci‑
dence of chronic heart failure.9 The clinical pre‑
sentation may be attributed to a specific distri‑
bution of atherosclerosis and predominance of 
NSTEMI as a clinical presentation of CAD, which 
was confirmed in the present study. It was recent‑
ly demonstrated that patients with an NSTEMI 
of the treating cardiologist. In conclusion, 2 is‑
sues should be highlighted as the main reason for 
the relatively low incidence of COPD in this group 
of patients, namely, low compliance of patients 
and insufficient awareness of the problem among 
physicians dealing with those patients in invasive 
cardiology units.
Culprit artery characterization and increased risk 
of repeat percutaneous coronary intervention 
The current study confirmed that patients with 
COPD are characterized by greater risk of dissem‑
inated coronary atherosclerosis. The Gensini score 
increases in patients with a more advanced stage 
of COPD and is the highest at stage D.26,27 Addi‑
tionally, we noted that patients with COPD pre‑
sented significantly higher rates of re ‑stenosis 
and in ‑stent thrombosis, while those rates were 
lower in the case of de ‑novo culprit lesions be‑
fore the PCI procedure. Similar observations were 
reported by Enriquez et al,25 who noted that pa‑
tients with COPD had a 30% higher risk of death 
and a 20% increased risk of undergoing repeat re‑
vascularization 1 year after PCI. The most reason‑
able explanation seems to be the increased num‑
ber of smokers among patients with COPD and 
other proatherosclerotic risk factors. Apart from 
the fact that more cigarette smokers were found 
among patients with COPD, the disease itself is 
considered to be a prothrombotic state and may 
therefore increase the risk of restenosis and in‑
‑stent thrombosis.28 In general, cigarette smoking 
is considered to be associated with the progres‑
sion of CAD and restenosis following PCI. How‑
ever, studies on patients with CAD have reported 
FIGURE 5 Multivariable analysis of predictors of multivessel disease with and without left main coronary artery involvement and separate left main 
coronary artery in patients referred for percutaneous coronary intervention on admission 
Abbreviations: Abbreviations: see TABLE 1 and FIGURE 2
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the preparation and writing of the manuscript.
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presentation of CAD on admission were more of‑
ten diagnosed with MVD of the coronary arteries 
compared with patients with STEMI.39
Periprocedural effectiveness In the  current 
study, the periprocedural effectiveness assessed 
by the TIMI flow grade was poorer in patients 
with COPD compared with those without COPD. 
It was mainly related to the type of atherosclero‑
sis. In the COPD group, we noticed a higher rate 
of MVD and LMCA disease as compared with 
the non ‑COPD group. Additionally, the main 
clinical presentation in the COPD group was 
NSTEMI, whereas the STEMI rate was higher 
in the non ‑COPD group. Furthermore, the high‑
er rate of restenosis and in ‑stent thrombosis on 
admission in the COPD group negatively affected 
the effectiveness rate assessed by the TIMI score.
Limitations The ORPKI database does not specif‑
ically define restenosis and in ‑stent thrombosis, 
and the definitions are usually at the discretion 
of the operators. No independent angiographic 
core laboratory analysis was performed. The di‑
agnosis of COPD was based on the previous diag‑
nosis and was not updated by spirometry; how‑
ever, on the other hand, it reflects the real inci‑
dence of COPD in the analyzed group of patients 
in the Polish population. The other significant lim‑
itation of the study is the lack of in ‑hospital peri‑
operative care and follow ‑up data, which substan‑
tially decreases the quality of the study. Howev‑
er, we were unable to collect those data because 
we did not have access to patients’ identification 
documents.
Conclusions Patients undergoing PCI are at an 
increased risk of disseminated atherosclerosis 
and LMCA involvement in comparison with in‑
dividuals without COPD. Restenosis and in ‑stent 
thrombosis are more common, whereas de ‑novo 
lesions are less common in patients with COPD 
referred for PCI, as compared with those with‑
out COPD. COPD is an independent predictor of 
restenosis in patients with a history of PCI and 
currently referred for PCI. Coronary atheroscle‑
rosis in patients with COPD is more disseminated 
and tends to involve the LMCA more often when 
compared with patients without COPD. Patients 
with suspected COPD who are hospitalized in in‑
vasive cardiology units should receive special care 
in terms of the diagnosis and treatment of COPD, 
which may improve their long ‑term results after 
PCI in the future.
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